

**Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)**

Taiji Sakamoto, Masahiko Shimura, Shigehiko Kitano, Masahito Ohji, Yuichiro Ogura, Hidetoshi Yamashita, Makoto Suzaki, Kimie Mori, Yohei Ohashi, Poh Sin Yap, Takeumi Kaneko, Tatsuro Ishibashi, for the MERCURY Study Group

**Corresponding author:**

Taiji Sakamoto

Department of Ophthalmology, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan

Tel: +81 99-275-5402

Fax: +81 99-265-4894

Email: [tsakamot@m3.kufm.kagoshima-u.ac.jp](mailto:tsakamot@m3.kufm.kagoshima-u.ac.jp)

**Online Resource 9.** Anti-VEGF treatment and summary of other adjunctive

DME treatments from baseline to month 11 (safety set)

|                                                                   | <b>PTE</b>     | <b>STE</b>     |
|-------------------------------------------------------------------|----------------|----------------|
|                                                                   | <b>N = 209</b> | <b>N = 61</b>  |
| Number of anti-VEGF injections (including ranibizumab)            |                |                |
| Mean ± SD                                                         | 3.6 ± 2.4      | 2.8 ± 1.8      |
| Median (IQR)                                                      | 3.0 (2.0, 5.0) | 2.0 (1.0, 4.0) |
| Number of ranibizumab injections                                  |                |                |
| Mean ± SD                                                         | 3.2 ± 2.0      | 2.4 ± 1.5      |
| Median (IQR)                                                      | 3.0 (2.0, 4.0) | 2.0 (1.0, 3.0) |
| Number of eyes with other adjunctive DME treatments, <i>n</i> (%) |                |                |
| Any other DME treatment                                           | 88 (42.1)      | 23 (37.7)      |
| Grid/focal laser photocoagulation                                 | 30 (14.4)      | 7 (11.5)       |
| Intravitreal/subtenon steroid injection                           | 29 (13.9)      | 6 (9.8)        |
| Vitrectomy                                                        | 8 (3.8)        | 4 (6.6)        |
| Panretinal photocoagulation                                       | 43 (20.6)      | 13 (21.3)      |
| Other                                                             | 8 (3.8)        | 1 (1.6)        |

DME, diabetic macular oedema; IQR, interquartile range; PTE, primary treated eye; SD, standard deviation; STE, secondary treated eye; VEGF, vascular endothelial growth factor.